ONYX Pharmaceuticals 8-K Departure of Directors or Certain Officers

EXHIBIT 10.19

Base Salaries and Bonus Potential for Fiscal Year 2010, Cash Bonuses for Fiscal Year 2009 and 2010 Equity Compensation Awards for Named Executive Officers

					Stock		Restricted
					Option(1)		Stock
	2010		2009		Grant		Award(2)
Name and Title	Salary		Bonus		(shares)		(shares)
N. Anthony Coles, M.D. (3) President and Chief Executive Officer	$	676,000	$	780,000		147,000		21,000
Matthew K. Fust (3) Executive Vice President and Chief Financial Officer	$	434,700	$	219,000		45,500		6,500
Judy Batlin (3) Vice President of Organizational Learning, Development, and Human Resources	$	329,100	$	129,000		31,500		4,500
Laura Brege (3) Executive Vice President and Chief Operating Officer	$	475,200	$	244,000		56,000		8,000
Juergen Lasowski (3) Senior Vice President, Corporate Development	$	391,000	$	180,000		42,000		6,000

(1)	One-eighth of the shares subject to the stock options will vest on the six month anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 42 months.
(2)	One-third of the shares subject to the restricted stock award will vest on the one year anniversary of the date of grant and the remaining shares will vest in two equal installments on the second and third anniversaries of the date of grant.
(3)	The 2010 bonus potential percentage remained at 100% for N. Anthony Coles. For each of the other named executive officers, the 2010 bonus potential was increased by 5% to 50%, 40%, 50% and 45%, respectively, of their 2010 annual salaries.